Press release: Curetis’ Subsidiary Ares Genetics Introduces NGS
Services for Pharma and Public Health Sector at Upcoming ECCMID
2019
- Strain-typing and AMR detection of clinical isolates
based on ARESdb
- Set-up of own NGS service laboratory in Vienna,
Austria
Vienna, Austria, Holzgerlingen, Germany,
and Amsterdam, The Netherlands, April 12, 2019, 08:00 CET
– Ares Genetics GmbH (Ares Genetics), a Curetis Group Company
(Curetis N.V.; EURONEXT: CURE), today announced the introduction of
new service offerings in molecular microbiology at the upcoming
29th European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID), which will take place in Amsterdam, the
Netherlands, on April 13-16, 2019.
From mid-2019, Ares Genetics will offer its
ARESupa Universal Pathogenome Assay for whole-genome sequencing of
bacterial strains isolated from clinical specimens. Applications
will be in epidemiology, infection control, and outbreak analysis
for customers in the public health sector and the pharmaceutical
industry. Based on the genetic profile of the respective clinical
isolate, ARESupa precisely identifies the bacterial strain and
detects antimicrobial resistance (AMR). Ares Genetics expects that
ARESupa will greatly facilitate the monitoring of AMR evolution and
spreading at the molecular level and provide rapid insights into
origin and dynamics of outbreaks of critical, often multi-drug
resistant pathogens in hospitals and care facilities.
ARESupa combines next-generation sequencing
(NGS) with data analysis and interpretation powered by ARESdb, Ares
Genetics’ AI-powered reference database on the genetics of
antimicrobial resistance. ARESdb currently covers detailed
whole-genome sequencing data of more than 35,000 bacterial strains,
including quantitative data on the resistance phenotype for more
than 100 antibiotics.
ARESupa will be offered out of Ares Genetics’
NGS service laboratory currently being set up in Vienna, Austria.
The NGS service laboratory will be headed by Dr. Johannes
Weinberger, who recently joined Ares Genetics from the Austrian Red
Cross where he set up an NGS facility for the Department of
Histocompatibility and Immunogenetics. He brings about ten years of
experience with NGS technologies in the public sector as well as
the healthcare industry.
While ARESupa initially is offered for
non-diagnostic uses in the public health sector and the
pharmaceutical industry, the Company is also working on an ARESupa
laboratory-developed test (LDT) for the detection of pathogens and
AMR in severe hospital-acquired infections that will initially be
launched for selected high-need indications that are difficult to
diagnose with conventional methods.
“Already today, there is wide-spread acceptance
of the benefits of NGS for AMR surveillance, pathogen epidemiology,
the tracking of outbreaks as well as for antimicrobial drug
development,” explained Dr. Andreas Posch, Managing Director and
CEO of Ares Genetics. “Hence, launching our Universal Pathogenome
Assay NGS services for isolate identification, typing and
quantitative genetic AMR profiling is an important milestone in the
execution of our business plan that ultimately aims at providing
universal NGS-based infectious disease diagnostics,” Dr. Posch
added.
“We expect that our new NGS service laboratory
will greatly accelerate our projects with pharmaceutical companies
such as Sandoz as well as collaborations with diagnostics industry
players,” said Dr. Achim Plum, Chief Business Officer of the
Curetis Group and Managing Director of Ares Genetics. “The ability
to perform NGS in our own laboratory comes timely as we are in
discussions with numerous companies on further projects using our
expanded service offerings.”
###
Ares Genetics at ECCMID 2019
For more information on ARESupa and Ares
Genetics licensing and service offerings for the diagnostics and
pharmaceutical industries visit Ares Genetics at the Curetis Group
Booth (Booth #1.65) at ECCMID 2019 in Amsterdam, Netherlands, on
April 13-16, 2019.
About Curetis and Ares
Genetics
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia, and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH offers next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence tools.
For further information, please
visit www.curetis.com
and
www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor an offer to subscribe for securities and neither this
document nor any part of it should form the basis of any investment
decision in Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements.” These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes,”
“estimates,” “anticipates,” “expects,” “intends,” “targets,” “may,”
“will,” or “should” and include statements Curetis makes concerning
the intended results of its strategy. By their nature,
forward-looking statements involve risks and uncertainties and
readers are cautioned that any such forward-looking statements are
not guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact details
Curetis Max-Eyth-Str. 4271088 Holzgerlingen, GermanyTel. +49
7031 49195-10pr@curetis.com or ir@curetis.comwww.curetis.com
- www.unyvero.com
International Media & Investor
InquiriesakampionDr. Ludger Wess / Ines-Regina Buth
Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel. +49
30 23 63 27 68
- 20190412_PR_AresGenetics_ECCMID_final_approved